A Phase III, Randomized, Controlled, Double-Blind Study Evaluating the Safety of Two Doses of Apixaban for Secondary Prevention of Cancer Related Venous Thrombosis in Subjects Who Have Completed at Least Six Months of Anticoagulation Therapy
Phase of Trial: Phase III
Latest Information Update: 13 Jul 2018
At a glance
- Drugs Apixaban (Primary)
- Indications Deep vein thrombosis
- Focus Adverse reactions
- 08 May 2018 Planned End Date changed from 1 May 2020 to 1 May 2022.
- 27 Oct 2017 Planned End Date changed from 1 Oct 2020 to 1 May 2020.
- 27 Oct 2017 Status changed from not yet recruiting to recruiting.